Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.

被引：1
|
作者：
Krug, Utz [1 ]
Knoblauch, Nicola [1 ]
Gerss, Joachim [1 ]
Schliemann, Christoph [1 ]
Wiebe, Stefanie [1 ]
Mueller-Tidow, Carsten [1 ]
Berdel, Wolfgang E. [1 ]
机构：
[1] Univ Hosp Muenster, Munster, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
  • [2] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Berdel, Andrew F.
    Koch, Raphael
    Gerss, Joachim
    Hentrich, Marcus
    Peceny, Rudolf
    Bartscht, Tobias
    Steffen, Bjoern
    Bischoff, Marina
    Spiekermann, Karsten
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Kewitz, Tobias
    Butterfass-Bahloul, Trude
    Serve, Hubert
    Lenz, Georg
    Berdel, Wolfgang E.
    Krug, Utz
    Schliemann, Christoph
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 63 - 72
  • [3] Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
    Takahashi, Koichi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Kadia, Tapan
    DiNardo, Courtney
    Jabbour, Elias
    Pierce, Sherry
    Estrov, Zeev
    Konopleva, Marina
    Andreeff, Michael
    Ravandi, Farhad
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03): : 163 - 168
  • [4] A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
    Schliemann, Christoph
    Gerss, Joachim
    Wiebe, Stefanie
    Mikesch, Jan-Henrik
    Knoblauch, Nicola
    Sauer, Tim
    Angenendt, Linus
    Kewitz, Tobias
    Urban, Marc
    Butterfass-Bahloul, Trude
    Edemir, Sabine
    Vehring, Kerstin
    Mueller-Tidow, Carsten
    Berdel, Wolfgang E.
    Krug, Utz
    PLOS ONE, 2016, 11 (10):
  • [5] LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A RETROSPECTIVE SINGLE CENTER ANALYSIS
    Jakob, C.
    Peinert, S.
    Breywisch, F.
    Guenther, B.
    Dittberner, K.
    Boger, L.
    Rothmann, F.
    Maschmeyer, G.
    HAEMATOLOGICA, 2015, 100 : 386 - 386
  • [6] LOW-DOSE CYTARABINE VERSUS INTENSIVE CHEMOTHERAPY IN THE TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA IN THE ELDERLY
    TILLY, H
    CASTAIGNE, S
    BORDESSOULE, D
    CASASSUS, P
    LEPRISE, PY
    TERTIAN, G
    DESABLENS, B
    HENRYAMAR, M
    DEGOS, L
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 272 - 279
  • [7] Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
    Yamauchi, Takahiro
    Yoshida, Chikashi
    Usuki, Kensuke
    Takada, Satoru
    Matsumura, Itaru
    Dobashi, Nobuaki
    Miyazaki, Yasushi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Asou, Norio
    Kuroda, Junya
    Ichikawa, Satoshi
    Komatsu, Norio
    Mendes, Wellington
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Jiang, Qi
    Wei, Andrew
    Ishizawa, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1372 - 1382
  • [8] Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy
    Wei, Andrew
    Strickland, Stephen A.
    Hou, Jing-Zhou
    Fiedler, Walter
    Lin, Tara L.
    Walter, Roland B.
    Enjeti, Anoop K.
    Hong, Wan-Jen
    Chyla, Brenda
    Popovic, Relja
    Fakouhi, Kaffa
    Xu, Tu
    Hayslip, John
    Roboz, Gail J.
    BLOOD, 2018, 132
  • [9] A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
    Hall, M. R.
    Dehbi, H. -M.
    Banerjee, S.
    Lord, R.
    Clamp, A.
    Ledermann, J. A.
    Nicum, S.
    Lilleywhite, R.
    Bowen, R.
    Michael, A.
    Feeney, A.
    Glasspool, R.
    Hackshaw, A.
    Rustin, G.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 692 - 698
  • [10] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
12345